Post-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine: more than 4 years of experience

por Angelo, Maria-Genalin, Zima, Julia, Tavares Da Silva, Fernanda, Baril, Laurence, Arellano, Felix
Publicado 2014

Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme

por Angelo, Maria-Genalin, David, Marie-Pierre, Zima, Julia, Baril, Laurence, Dubin, Gary, Arellano, Felix, Struyf, Frank
Publicado 2014

Investigating Reports of Complex Regional Pain Syndrome: An Analysis of HPV-16/18-Adjuvanted Vaccine Post-Licensure Data

por Huygen, Frank, Verschueren, Kristin, McCabe, Candida, Stegmann, Jens-Ulrich, Zima, Julia, Mahaux, Olivia, Van Holle, Lionel, Angelo, Maria-Genalin
Publicado 2015

Safety of the AS04-adjuvanted human papillomavirus (HPV)-16/18 vaccine in adolescents aged 12–15 years: end-of-study results from a community-randomized study up to 6.5 years

por Bi, Dan, Apter, Dan, Eriksson, Tiina, Hokkanen, Mari, Zima, Julia, Damaso, Silvia, Soila, Maaria, Dubin, Gary, Lehtinen, Matti, Struyf, Frank
Publicado 2019

Risk of new onset autoimmune disease in 9- to 25-year-old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom

por Willame, Corinne, Rosillon, Dominique, Zima, Julia, Angelo, Maria-Genalin, Stuurman, Anke L., Vroling, Hilde, Boggon, Rachael, Bunge, Eveline M., Pladevall-Vila, Manel, Baril, Laurence
Publicado 2016

Safety of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in adolescents aged 12–15 years: Interim analysis of a large community-randomized controlled trial

por Lehtinen, Matti, Eriksson, Tiina, Apter, Dan, Hokkanen, Mari, Natunen, Kari, Paavonen, Jorma, Pukkala, Eero, Angelo, Maria-Genalin, Zima, Julia, David, Marie-Pierre, Datta, Sanjoy, Bi, Dan, Struyf, Frank, Dubin, Gary
Publicado 2016